PURPOSE: This study aims to develop a low molecular weight folate receptor (FR) contrast agent for MR tumor imaging. PROCEDURES: Gadolinium-tetraazacyclododecane tetraacetic acid (Gd.DOTA) was conjugated to folic acid to create Gd.DOTA.Folate. The efficacy of Gd.DOTA.Folate to bind FR was evaluated in vitro by inductively coupled mass spectrometry (ICP-MS) and in vivo by magnetic resonance imaging (MRI) tumor enhancement over 14 h, utilizing an overexpressing α-FR cell line (IGROV-1), compared to an α-FR-negative cell line (OVCAR-3). Gd.DOTA.Folate localization ex vivo was verified by laser ablation ICP-MS. RESULTS: ICP-MS confirmed Gd.DOTA.Folate uptake by IGROV-1 cells and competitive binding with free folic acid inhibited binding. IGROV-1 tumors showed an increase in R (1) at 2 h, which increased significantly over 14 h post-Gd.DOTA.Folate with clear enhancement on MR images. This was not observed in controls. CONCLUSION: These data support the use of FR-targeted small molecular weight MRI contrast agents for tumor imaging in vivo.
PURPOSE: This study aims to develop a low molecular weight folate receptor (FR) contrast agent for MR tumor imaging. PROCEDURES: Gadolinium-tetraazacyclododecane tetraacetic acid (Gd.DOTA) was conjugated to folic acid to create Gd.DOTA.Folate. The efficacy of Gd.DOTA.Folate to bind FR was evaluated in vitro by inductively coupled mass spectrometry (ICP-MS) and in vivo by magnetic resonance imaging (MRI) tumor enhancement over 14 h, utilizing an overexpressing α-FR cell line (IGROV-1), compared to an α-FR-negative cell line (OVCAR-3). Gd.DOTA.Folate localization ex vivo was verified by laser ablation ICP-MS. RESULTS: ICP-MS confirmed Gd.DOTA.Folate uptake by IGROV-1 cells and competitive binding with free folic acid inhibited binding. IGROV-1 tumors showed an increase in R (1) at 2 h, which increased significantly over 14 h post-Gd.DOTA.Folate with clear enhancement on MR images. This was not observed in controls. CONCLUSION: These data support the use of FR-targeted small molecular weight MRI contrast agents for tumor imaging in vivo.
Authors: Mary Jo Turk; Gert J Breur; William R Widmer; Chrystal M Paulos; Le-Cun Xu; Lee Ann Grote; Philip S Low Journal: Arthritis Rheum Date: 2002-07
Authors: Cyrus B Amoozegar; Tracy Wang; Matthew B Bouchard; Addason F H McCaslin; William S Blaner; Richard M Levenson; Elizabeth M C Hillman Journal: J Biomed Opt Date: 2012-09 Impact factor: 3.170
Authors: Xueming Wu; Susan M Burden-Gulley; Guan-Ping Yu; Mingqian Tan; Daniel Lindner; Susann M Brady-Kalnay; Zheng-Rong Lu Journal: Bioconjug Chem Date: 2012-08-01 Impact factor: 4.774
Authors: Gyula Tircsó; Enikő Tircsóné Benyó; Zoltán Garda; Jaspal Singh; Robert Trokowski; Ernő Brücher; A Dean Sherry; Éva Tóth; Zoltán Kovács Journal: J Inorg Biochem Date: 2020-02-20 Impact factor: 4.155
Authors: Andreas Matusch; Larissa S Fenn; Candan Depboylu; Martin Klietz; Sven Strohmer; John A McLean; J Sabine Becker Journal: Anal Chem Date: 2012-03-20 Impact factor: 6.986
Authors: Luke F Vistain; Matthew W Rotz; Richa Rathore; Adam T Preslar; Thomas J Meade Journal: Chem Commun (Camb) Date: 2016-01-04 Impact factor: 6.222
Authors: M Sahuri-Arisoylu; L P Brody; J R Parkinson; H Parkes; N Navaratnam; A D Miller; E L Thomas; G Frost; J D Bell Journal: Int J Obes (Lond) Date: 2016-02-12 Impact factor: 5.095